Sabby Management’s CorMedix CRMD Stock Holding History

Sabby Management’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-839	Closed	-$623K	–	166
2020 Q4	$623K	Buy	839 +603	+256%	+$4.1K	0.12%	61
2020 Q3	$142K	Buy	+236	New	+$1.19K	0.02%	110

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Sabby Management's CRMD Position: Q4 2019 in Review

Sabby Management sold out of CorMedix (CRMD) in Q4 2019, closing a stake of 249,198 shares — an estimated $1.59M sold.

Sabby Management first reported a position in CRMD in Q2 2017 and held it in 5 quarters. The position peaked at $1.82M in Q2 2017. 62 funds tracked by Wall St. Rank hold CRMD as of Q4 2019.

Sabby Management reported no remaining CorMedix position as of Q4 2019 after selling out during the quarter.
Sabby Management sold 249,198 CorMedix shares in Q4 2019, an estimated $1.59M.
Sabby Management first reported a position in CorMedix in Q2 2017 and held it in 5 quarters.
Sabby Management's CorMedix position peaked at $1.82M in Q2 2017.
62 funds tracked by Wall St. Rank held CorMedix as of Q4 2019.

Based on Sabby Management's 13F filing for Q4 2019, filed 14 Feb 2020.